OncoMatch/Clinical Trials/NCT06326411
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
Is NCT06326411 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies NST-628 for oncology.
Treatment: NST-628 — This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment options.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Melanoma
Non-Small Cell Lung Carcinoma
Glioblastoma
Tumor Agnostic
Biomarker criteria
Required: NRAS activating mutation
Activating NRAS mutations
Required: BRAF select alterations
Select BRAF alterations
Required: KRAS activating mutation
Solid tumors with KRAS activating mutations
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: MEK inhibitor
prior treatment with any MEK or BRAF inhibitor
Cannot have received: BRAF inhibitor
prior treatment with any MEK or BRAF inhibitor
Cannot have received: chemotherapy
Exception: within 28 days of Cycle 1 Day 1
Chemotherapy, radiation, gene therapy, vaccine therapy, or anti-cancer antibodies / ADCs within 28 days of Cycle 1 Day 1
Cannot have received: radiation therapy
Exception: within 28 days of Cycle 1 Day 1
Chemotherapy, radiation, gene therapy, vaccine therapy, or anti-cancer antibodies / ADCs within 28 days of Cycle 1 Day 1
Cannot have received: gene therapy
Exception: within 28 days of Cycle 1 Day 1
Chemotherapy, radiation, gene therapy, vaccine therapy, or anti-cancer antibodies / ADCs within 28 days of Cycle 1 Day 1
Cannot have received: vaccine therapy
Exception: within 28 days of Cycle 1 Day 1
Chemotherapy, radiation, gene therapy, vaccine therapy, or anti-cancer antibodies / ADCs within 28 days of Cycle 1 Day 1
Cannot have received: antibody-drug conjugate
Exception: within 28 days of Cycle 1 Day 1
Chemotherapy, radiation, gene therapy, vaccine therapy, or anti-cancer antibodies / ADCs within 28 days of Cycle 1 Day 1
Cannot have received: targeted small molecule agent
Exception: within 14 days or 5 half-lives of Cycle 1 Day 1
Targeted small molecule agents within 14 days or 5 half-lives of Cycle 1 Day 1
Lab requirements
Blood counts
adequate organ function
Kidney function
adequate organ function
Liver function
adequate organ function
Have adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UPMC Hillman Cancer Center · Pittsburgh, Pennsylvania
- UCSF Helen Diller Family Comprehensive Cancer Center · San Francisco, California
- UCLA Hematology/Oncology · Westwood, Los Angeles, California
- Sarah Cannon Research Institute at Health ONE · Denver, Colorado
- Yale Cancer Center · New Haven, Connecticut
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06326411 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior MEK inhibitor, BRAF inhibitor, chemotherapy disqualifies patients from enrollment.
Does this trial require NRAS?
Yes, NRAS activating mutation is a required biomarker for enrollment.
Does this trial require BRAF?
Yes, BRAF select alterations is a required biomarker for enrollment.
Does this trial require KRAS?
Yes, KRAS activating mutation is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify